Answers are grounded in this paper and cite their sources.
Observational study reveals daridorexant improves sleep quality in patients with chronic headaches, suggesting potential benefits for sleep management.
Aim There is an unquestionable, clinical and pathophysiological, relationship between sleep and primary headaches. We explored the effect of daridorexant, a novel dual orexin receptor antagonist, in patients with primary chronic headache and chronic insomnia. Methods Retrospective chart review of patients with primary chronic headache and insomnia who had started treatment with daridorexant 50 mg for their sleep disorder. Headaches were assessed using a calendar and sleep quality using the Patient Global Impression of Change (PGIC) scale (1 no benefit–7 absolute response). Results We included 12 patients (10 women; ages 36–72 years). In 6 (50%) patients, insomnia improved (PGIC ≥ 5); mean PGIC being 4.9. In contrast, only one patient (8.3%) experienced a response (≥50% reduction) in their headaches. Mild adverse events were seen in two patients. Conclusions In patients with primary chronic headaches, daridorexant improved the subjective quality of sleep in half of the patients but had no clear effect on the frequency or intensity of chronic headaches.
No takes yet. Share an insight, caveat, or question.
González-Quintanilla et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: